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neurodegenerative disease*The linkage between head trauma and neurodegeneration
represents not only an important public and military health
issue but also provides crucial clues for putative risk factors
for numerous late-life chronic brain disorders. Today, there
is now growing evidence that a single traumatic brain injury
(TBI) sustained early in life might trigger a cascade of
neurodegenerative processes. The outcomes may manifest
as dementia, Alzheimer’s dementia (AD), Lewy Body de-
mentia (LBD), or other motor neuron diseases many years
or decades later. The scientific and medical community
has known the effects of trauma on boxers since the 1920s.
Now, increasing number of studies are showing that even
mild repetitive trauma may lead to onset of symptoms in
some athletes as early as in their second decade of life.
The renewed interest in the idea that mild repetitive trauma
to the head can trigger not only chronic traumatic encepha-
lopathy (CTE) but also other neurodegenerative diseases is
indeed timely. This important recognition is reinforced by
the increased risk and prevalence of TBI and post-
traumatic stress disorder (PTSD) among young military
personnel associated with combat experiences.
Understanding the neurobiological mechanisms of the as-
sociation of TBI and PTSD with an increased risk of neuro-
degenerative disease has become a high priority for the U.S.
Army. Civilian public health research shares this military
health interest and highlights a common critical challenge:
the development of novel technologies for the early and ac-
curate identification of people with elevated risk for neuro-
degenerative diseases.
An early challenge for military and civilian health
research will be to unlock complex, intersecting associations
and interactions among multiple risk factors (such as pro-
teins, genes, and environment factors). This work will
require more robust and granular longitudinal data, the
collection of data parameters that may vary daily or hourly,
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opment of critical detection technologies. These tools will
enable individuals with elevated risk to make informed life-
style choices that limit head trauma exposures. Moreover,
the answers found in studies of trauma-induced neurodegen-
eration are likely to increase our understanding of the entire
spectrum of neurodegenerative diseases as well as other age-
associated chronic brain disorders [CBD].
Neurodegenerative diseases [ND], as a prototype for
other CBD, represent an important class of conditions for
healthcare systems due to their prolonged labor-intensive
care requirements and profound economic impact. These
conditions have severe psychosocial ramifications that may
span an entire human lifetime. Moreover, ND are emblem-
atic for a host of other long-lasting incapacitating conditions
that require a global response.
Leaders in governments, businesses and academia recog-
nize the need for a well-coordinated strategic international
plan. Moving forward, planning efforts should establish
financial mandates for strengthening the worldwide scienti-
fic capabilities, infrastructure, and resources for research and
development. Such investments will have the net-effect on
reducing the duration of chronic brain disorders and/or the
number of people at risk for these conditions. Budget outlays
should be coupled with sound legislative and policy initia-
tives to foster broader engagement through public–private
partnerships. History has proven that collaboration among
academic investigators, government, pharmaceutical, and
biotechnology companies is an essential ingredient in
advancing bold initiatives, particularly when resources are
limited.
International plans to combat Alzheimer’s dementia, TBI
and other CBD must address the pressing need to accelerate
breakthroughs for ever-earlier detection of individuals at risk
as well as a wide spectrum of intervention to limit the
progression of neurodegeneration before the onset of dis-
abilities or symptoms. The societal burden of these disor-
ders—spanning early-, middle- and late-life—merits
harmonized international planning efforts that should
encompass three related aims. The first is the development
of shared international research infrastructure resources
(IR2s). The second is related organizational managementeserved.
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sources. The third is expansion of global investigator net-
works that will optimally develop, exchange and
disseminate new knowledge. Building upon already existing
programs and initiatives, including those developed and
funded by the U.S. Department of Defense, Veterans Admin-
istration and the Department of Health and Human Services,
and by leveraging other existing international resources of-
fers the fastest pathway to meet these goals.
The discovery of risk factors, biomarkers, and surrogate
indices for neurodegeneration will be enhanced through
the development of a shared international research infra-
structure resource (IR2). One research application is the
combinatorial optimization and validation of disease
specific risk factors-biomarkers-surrogate indices matrices.
This challenge requires longitudinal, large-scale
(n . 100,000) international prospective clinical and obser-
vational data in order to have sufficient power and resolution
for modeling and hypothesis testing. Developing a suffi-
ciently large data reservoir to support specific (and varied)
research questions is essential for the rapid translation and
regulatory approval into useful, routine, clinical tools for ac-
curate prognosis and diagnostics of individuals. In this
example, to assure validation and regulatory market
approval, a key requirement for the research project using
a shared IR2 will be the availability of large and diverse
cohorts—spanning the lifespan—of heterogeneous popula-
tions. This will include healthy young-, middle- and late-
age adults as well as individuals at elevated risk of
developing neurodegenerative disease.
Conceptualizing and launching the organizational struc-
ture, administration and functional capabilities of this IR2
will depend on the recruitment of large numbers of volun-
teers to meet the data needs of multiple projects exploring
multiple hypotheses among diverse populations. The
shared IR2 will provide the world scientific community
an unprecedented opportunity to plan and execute a wide
range of population-based and naturalistic studies to solve
critical questions related to public health, aging and indi-
vidual brain disorders. The shared IR2 will have the capac-
ity to support various activities such as the discovery and
validation of biomarkers, epidemiological studies to assess
potential risk factors, and aid in the identification of indi-
viduals’ occupational specialties that reduce the likelihood
of head injuries.
The multi-factorial nature of CBDs will also require so-
phisticated computational capabilities for pattern analysisof various indicators, as has been the case in genomics and
proteomics studies. The goal will be to identify relevant
sets of indices so that when an intervention becomes avail-
able, appropriate individuals can be selected to test its effec-
tiveness. As instruments and biomarker progress to measure
neurodegeneration in the earliest stages of onset, questions
about the fundamental mechanisms that underlie CBD can
be more fully explored. This includes: a) understanding
why some neurons are, and others are not affected, b) the
precise nature or cause of the failure-disruption in the func-
tioning of some specific neural systems, while other
networks remain intact. Answers to these questions are
pivotal to the development effective preventive interven-
tions.
Sowhere to start? The next steps should focus on expand-
ing ongoing collaborative effort and build upon the experi-
ences gained from already-established, ongoing
international collaborative efforts, such as the Worldwide
Alzheimer Disease Neuroimaging Initiative (ADNI), the
U.S. Department of Defense-ADNI, the Alzheimer’s Asso-
ciation Global Biomarker Standardization Consortium and
the Global Alzheimer’s Association Interactive Network.
The transition of these and other shared IR2s into large
international enterprises will require new models of gover-
nance and financing to sustain multi-decade long operation.
The Alzheimer’s Association in partnership with Campaign
to Prevent Alzheimer’s by 2020 has taken the leadership in
launching one formal strategic planning process by
convening a workgroup on Big Data to Smart Data. Future
international planning efforts should remain focused on inte-
grating solutions from the worldwide collaborative research
enterprise, with a special emphasis on new models for
research finance. This convergence of efforts will speed
development of interventions to meet the urgent needs of
public and military health in combating Alzheimer’s demen-
tia and other neurodegenerative diseases.
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